Israel Englander Tyme Technologies, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

Shares

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.23 - $0.35 $71,847 - $109,332	-312,379 Reduced 59.4%	213,530 $60,000
Q1 2022 May 16, 2022	SELL	$0.28 - $0.68 $94,350 - $229,136	-336,966 Reduced 39.05%	525,909 $184,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.04 $334,389 - $579,607	-557,315 Reduced 39.24%	862,875 $520,000
Q3 2021 Nov 15, 2021	SELL	$0.99 - $1.38 $695,364 - $969,295	-702,388 Reduced 33.09%	1,420,190 $1.46 Million
Q2 2021 Aug 16, 2021	BUY	$1.14 - $1.87 $2.23 Million - $3.67 Million	1,960,455 Added 1209.24%	2,122,578 $2.67 Million
Q1 2021 May 17, 2021	BUY	$1.34 - $3.53 $217,244 - $572,294	162,123 New	162,123 $289,000
Q2 2020 Aug 14, 2020	SELL	$0.97 - $1.7 $33,004 - $57,842	-34,025 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.9 - $1.95 $30,622 - $66,348	34,025 New	34,025 $37,000
Q4 2019 Feb 14, 2020	SELL	$1.0 - $1.49 $15,869 - $23,644	-15,869 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$0.97 - $1.77 $355,427 - $648,563	-366,420 Reduced 95.85%	15,869 $18,000
Q2 2019 Aug 14, 2019	BUY	$0.96 - $1.89 $366,997 - $722,526	382,289 New	382,289 $466,000
Q4 2018 Feb 14, 2019	SELL	$2.01 - $4.21 $1.66 Million - $3.47 Million	-825,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$2.18 - $3.44 $163,500 - $258,000	-75,000 Reduced 8.33%	825,000 $2.29 Million
Q2 2018 Aug 14, 2018	SELL	$2.05 - $4.09 $1.34 Million - $2.66 Million	-651,315 Reduced 41.98%	900,000 $2.84 Million
Q1 2018 May 15, 2018	BUY	$2.12 - $7.0 $2.78 Million - $9.19 Million	1,313,190 Added 551.47%	1,551,315 $3.46 Million
Q4 2017 Feb 14, 2018	BUY	$3.25 - $7.3 $587,015 - $1.32 Million	180,620 Added 314.09%	238,125 $1.52 Million
Q3 2017 Nov 14, 2017	BUY	$4.08 - $9.47 $234,620 - $544,572	57,505	57,505 $304,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.